COVID-19 impacting Cell&Gene therapy manufacturing Webinar | molmed
Borsa di studio post-dottorale
PROSPETTO INFORMATIVO MolMed S.p.A.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHER
home | molmed
Molmed, la giapponese Agc supera il 50% in Opa - Il Sole 24 ORE
Aptamer-Based Antibacterial and Antiviral Therapy against Infectious Diseases | Journal of Medicinal Chemistry
Borsa, MolMed vola su espansione studio clinico in Usa - FIRSTonline
1 - [Note: this notice is the English translation of the official version of the 102 notice which will be in Italian language]
MolMed - YouTube
pg80-149_009.jpg
Overview of the Italian Primary Markets
Il 2019 è l'anno della svolta per MolMed - MilanoFinanza News
MolMed - Wikipedia
Modeling early stage atherosclerosis in a primary human vascular microphysiological system | Nature Communications
Innovazione, la Borsa corre con plastica e super batteri - Corriere.it
MolMed now part of AGC Biologics | LinkedIn
home | molmed
Half-Year Financial Report at June 30th, 2020
Will MolMed soon have its first Cell therapy on the Market?
COMUNICATO STAMPA
COMUNICATO STAMPA
Meeting agenda | molmed
European Population Genetic Substructure: Further Definition of Ancestry Informative Markers for Distinguishing among Diverse European Ethnic Groups | Molecular Medicine | Full Text
Molmed, opa della giapponese Agc per la biotech italiana Molmed - Wired | Wired Italia
Azioni MolMed: Quotazione, Andamento e Previsioni | Emanuele Perini
